Video wird geladen...
Video konnte nicht geladen werden
A newly published human trial looked at 197 patients with over 20 different types of cancer, including metastatic cancers. After six months using ivermectin and mebendazole, 84% saw regression, stabilization, or no detectable cancer progression. Why isn’t this making national headlines? If these results are real, then we need... show more
47,117 Aufrufe • vor 2 Monaten •via X (Twitter)
0 Kommentare
Keine Kommentare verfügbar
Kommentare vom Original-Post werden hier angezeigt
![Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure](https://image.24vids.com/tw-2076674479695024226/amplify_video_thumb/2076674231136333824/img/S83Z7cJ1QdkerVCs.jpg)
![Oncologist Dr. William Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics, and they respond very well... [And] why do these antiparasitics work?" Todd Callender: "Cancer's a parasite?" Makis: "That's one possibility." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with attorney Todd Callender posted to the VaxxCHOICE (VaxxCHOICE) Rumble channel on November 21, 2025. ---------------Partial transcription of clip---------------- Dr. Makis: "The turbo cancers after the COVID vaccines do respond to the antiparasitics and they respond very well. This is, you know, whether it's ivermectin, fenbendazole or mebendazole, these patients are responding. "Now this is very important because patients who've developed cancer after taking Covid vaccines, they don't respond usually to conventional treatments. That's one of the hallmarks of turbo cancer is they present at a very late stage. These are extremely rapidly growing tumors. They're coming in at stage four. And it's whether it's young women with breast cancer, women in their 20s, something we've never seen before, young women with, men and women with colon cancer in their 20s and 30s. "Again, we've never seen—" Callender: "Two- year-olds, I've heard of two- year-olds with colon cancer—" Dr. Makis: "—we've never seen this before. That's the incredible part. And they're not responding to conventional treatments. So, they're not responding to chemo, they're not responding to radiation therapy, immunotherapy, or if they do response, they have a very, very short response time or remission time. And then the cancer comes roaring back. "And in a lot of these tragic cases, the patient dies within six months. This is another one of the features of turbo cancer is the prognosis is extremely poor if you go the conventional route. So you need something else. Now when you're using antiparasitics, for cancer, the dose is higher than the dose you would use to treat parasites or to treat Covid. So I give just a rule of thumb for ivermectin, for example, it's about five times the dose that you would need for cancer, about 5 to 10 times the dose than if you were just treating parasites or viruses. "And to go into the— why does it work? Why do these antiparasitics work?" Callender: "Cancer's a parasite?" Dr. Makis: "Well, that's one possibility. But there's more to it than that because, out of the 400 papers that have been published, a lot of those researchers look at the mechanisms. They are trying to identify the mechanisms of how ivermectin is treating these cancers. "And you've got, for example, there was one study published a few years ago, Mexican researchers, again, you're not going to see this done in the United States, Mexico. Mexican researchers took 28 different cancer cell lines, applied ivermectin to them, and all of them responded. Now to various degrees, you had breast cancer and ovarian cancer actually responding the most to ivermectin. You had the most cancer cell killing when they were exposed to ivermectin. "But when they look at the mechanisms, they've identified a number of interesting things. For example, ivermectin shuts down and kills cancer stem cells. Now, this is important because cancer stem cells are the reason chemotherapy doesn't work. When you have stage four pancreatic cancer, stage four ovarian cancer, and you go to your oncologist, they will tell you, we will give you chemo, but we can't cure you. It's palliative chemo. It'll buy you an extra six months, an extra 12 months of life. "The reason why they say that is why the chemo is palliative, not curative. It's is because chemo cannot kill cancer stem cells, which are not rapidly dividing. Chemo will kill everything that's rapidly dividing, but cancer stem cells are not rapidly dividing. And so the chemo will kill the rapidly dividing tumor cells, and it'll leave the cancer stem cells alone, while the cancer stem cells will start rapidly dividing a year later, two years later, they're going to spread to other parts of the body. Suddenly you've got recurrence, you've got metastases. Ivermectin will shut down and kill cancer stem cells. "So imagine you, added to your chemo regimen, and now you've essentially turned what's palliative chemo or a palliative situation to potentially a curative situation. And I really do believe I've come to the point, having helped over 7,000 cancer patients in the last year, I've come to the point where I could confidently say that stage 4 pancreatic cancer is curable, stage 4 ovarian cancer is curable, stage 4 colon cancer, lung cancer. These cancers are curable. I think if you add repurposed drugs, you add antiparasitics, you can turn these into curable situations. "Now, of course, we have to prove that. We have to do the research, do the publications. But in the meantime, I say stage 4 cancer patients don't have 10 years to wait for mainstream oncology or mainstream medicine to catch up with what we're seeing already clinically, in practice."](https://image.24vids.com/tw-1993127013713166353/amplify_video_thumb/1993124339852754944/img/m5izGyXtNBTWkWd4.jpg)
![Oncologist Dr. William Makis describes getting attacked by the president of City of Hope cancer centers for publishing success stories using antiparasitics to treat turbo cancers: "These antiparasitics are being heavily attacked and are being suppressed every time I mention ivermectin, mebendazole, [and] fenbendazole. And I have hundreds of success stories...." This clip of Dr. Makis, a radiologist, oncologist, and cancer researcher, is taken from a panel discussion posted to the World Council for Health Rumble channel on November 24, 2025. ---------------Partial transcription of clip---------------- "So these antiparasitics are being heavily attacked, and are being suppressed every time I mention ivermectin, mebendazole, fenbendazole, and I have hundreds of success stories. I get attacked. I get attacked by mainstream doctors and mainstream oncologists. "And just going back to what Kevin McKernan said about this phenomenon of trying to retract papers, get good papers retracted, I've had this happen to me very recently. We published recently a paper on fenbendazole. Three cases of stage four cancer patients who had failed three or four or five lines of chemotherapy, and mainstream oncology regimens. These cancer patients were dying. They took fenbendazole and they became cancer free. And we followed them up, up to three years. They stayed cancer three for up to three years. So we had three cases. We published this paper a few months ago. This was only the second paper published on the antiparasitic fenbendazole in the past five years with human cases. The first one was published by Stanford University in 2021. And so they had published three cases in 2021. We published three cases in 2025. Within a month or two of the publication of our paper. Now it passed peer review and it was published. We were attacked by the editor of the paper, who's actually the president of the City of Hope cancer centers in the United States, in Atlanta, Chicago, and Phoenix. "This was Dr. Maurice [Maurie] Markman, President of City of Hope, so a big time oncologist, with a lot of, you know, big pharma funding behind him. He said he's going to pull the paper. And they didn't have a good reason to pull the paper. In fact, the reason that they were putting was that I was giving, you know, medical advice to other cancer patients with fenbendazole. And so that was some kind of a conflict of interest. And because, you know, that wasn't declared in the way they liked, that they were going to pull the paper. "And so, you know, this is an attack. We're going to see these attacks not just on Kevin McKernan and David Speicher's work in trying to make the link between Covid vaccines and these turbo cancers. But even those of us who are going to try to treat these patients, and help these patients and try to get that work published with antiparasitics and these turbo cancers, we're being attacked, and our papers are being attacked for retraction as well." #Fenbendazole #Ivermectin #Cancercure](https://image.24vids.com/tw-2072362082264047725/amplify_video_thumb/2072361878592933888/img/oHkZrV5xM-aB9mvY.jpg)
![Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."](https://image.24vids.com/tw-1992289499234353444/amplify_video_thumb/1992288090514427904/img/AnV6ey4me_UypXaN.jpg)
